摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Asialo GM1 | 71012-19-6

中文名称
——
中文别名
——
英文名称
Asialo GM1
英文别名
N-[(E)-1-[(3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxyoctadec-4-en-2-yl]octadecanamide
Asialo GM1化学式
CAS
71012-19-6
化学式
C62H114N2O23
mdl
——
分子量
1255.6
InChiKey
VELGMVLNORPMAO-JTFNWEOFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    氯仿:甲醇 (2:1): 可溶

计算性质

  • 辛醇/水分配系数(LogP):
    6.5
  • 重原子数:
    87
  • 可旋转键数:
    45
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.94
  • 拓扑面积:
    395
  • 氢给体数:
    15
  • 氢受体数:
    23

安全信息

  • 安全说明:
    S22,S24/25

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    ganglioside GM1乙酸盐 为溶剂, 反应 8.0h, 以giving about 2.6 mg of asialo GM1 as a white powder的产率得到Asialo GM1
    参考文献:
    名称:
    Process for producing asialo GM1
    摘要:
    本发明提供了一种制备非唾液酸G.sub.M1的方法,其特征在于允许神经氨酸酶同工酶L作用于神经节苷脂以产生非唾液酸G.sub.M1。
    公开号:
    US05275939A1
  • 作为试剂:
    描述:
    双唾液酸神经节苷酯GD1A乙酸盐 、 在 Asialo GM1氯仿甲醇 作用下, 以 氯仿 为溶剂, 反应 1.0h, 以giving 2.0 mg of asialo GM1 as a white powder的产率得到Asialo GM1
    参考文献:
    名称:
    Process for producing asialo GM1
    摘要:
    本发明提供了一种制备非唾液酸G.sub.M1的方法,其特征在于允许神经氨酸酶同工酶L作用于神经节苷脂以产生非唾液酸G.sub.M1。
    公开号:
    US05275939A1
点击查看最新优质反应信息

文献信息

  • Retargeting of viruses or VLPs
    申请人:Deutsches Primatenzentrum GmbH Leibniz-Institut für Primatenforschung
    公开号:US10975359B2
    公开(公告)日:2021-04-13
    The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (vlp) carrying on its surface at least one targeting molecule that binds to a cell of interest. Furthermore, the present invention relates to a composition comprising such a polyomavirus or polyomavirus-derived vlp and to the use of the polyomavirus or polyomavirus-derived vlp of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived vlp or the composition of the invention.
    本发明涉及一种生产多瘤病毒或多瘤病毒衍生病毒样颗粒(vlp)的方法,该病毒样颗粒表面携带至少一种与相关细胞结合的靶向分子。此外,本发明还涉及一种包含这种多瘤病毒或多瘤病毒衍生的病毒样颗粒的组合物,以及本发明的多瘤病毒或多瘤病毒衍生的病毒样颗粒或本发明的组合物作为药物的用途。本发明还涉及一种包含多瘤病毒或多瘤病毒衍生 vlp 或本发明组合物的试剂盒。
  • RETARGETING OF VIRUSES OR VLPS
    申请人:Deutsches Primatenzentrum GmbH (DPZ) - Leibniz-Institut für Primatenforschung
    公开号:EP3577217B1
    公开(公告)日:2021-04-14
  • RETARGETING OF VIRUSES OR VLPs
    申请人:DEUTSCHES PRIMATENZENTRUM GMBH (DPZ) - LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG
    公开号:US20190352617A1
    公开(公告)日:2019-11-21
    The present invention relates to a method of producing a polyomavirus or polyomavirus-derived virus-like particle (VLP) carrying on its surface at least one targeting molecule that binds to a cell of interest, the method comprising the step of contacting the polyomavirus or polyomavirus-derived VLP with (i) the targeting molecule, wherein the at least one targeting molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; or (ii) a first interaction molecule, wherein the first interaction molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; and the at least one targeting molecule, wherein the at least one targeting molecule is conjugated to a second interaction molecule capable of interacting with the first interaction molecule. The present invention further relates to a polyomavirus or polyomavirus-derived virus-like particle (VLP), wherein the virus or VLP carries on its surface at least one targeting molecule that binds to a cell of interest, as well as to a polyomavirus or polyomavirus-derived VLP obtained or obtainable by the method of the invention. Furthermore, the present invention relates to a composition comprising said polyomavirus or polyomavirus-derived VLP and to the use of the polyomavirus or polyomavirus-derived VLP of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived VLP or the composition of the invention.
  • [EN] RETARGETING OF VIRUSES OR VLPs<br/>[FR] RECIBLAGE DE VIRUS OU DE PPV
    申请人:DEUTSCHES PRIMATENZENTRUM GMBH DPZ LEIBNIZ INST FUER PRIMATENFORSCHUNG
    公开号:WO2018141849A1
    公开(公告)日:2018-08-09
    The present invention relates to a method of producing a polyomavirus or polyomavirus- derived virus-like particle (VLP) carrying on its surface at least one targeting molecule that binds to a cell of interest, the method comprising the step of contacting the polyomavirus or polyomavirus-derived VLP with (i) the targeting molecule, wherein the at least one targeting molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; or (ii) a first interaction molecule, wherein the first interaction molecule is glycosylated with at least one glycosyl residue that is recognised by the polyomavirus or polyomavirus-derived VLP; and the at least one targeting molecule, wherein the at least one targeting molecule is conjugated to a second interaction molecule capable of interacting with the first interaction molecule. The present invention further relates to a polyomavirus or polyomavirus-derived virus-like particle (VLP), wherein the virus or VLP carries on its surface at least one targeting molecule that binds to a cell of interest, as well as to a polyomavirus or polyomavirus-derived VLP obtained or obtainable by the method of the invention. Furthermore, the present invention relates to a composition comprising said polyomavirus or polyomavirus-derived VLP and to the use of the polyomavirus or polyomavirus-derived VLP of the invention or the composition of the invention for use as a medicament. The present invention further relates to a kit comprising the polyomavirus or polyomavirus-derived VLP or the composition of the invention.
  • Process for producing asialo GM1
    申请人:Marukin Shoyu Co., Ltd.
    公开号:US05275939A1
    公开(公告)日:1994-01-04
    The present invention provides a process for preparing asialo G.sub.M1 characterized in that neuraminidase isozyme L is allowed to act on gangliosides to produce asialo G.sub.M1.
    本发明提供了一种制备非唾液酸G.sub.M1的方法,其特征在于允许神经氨酸酶同工酶L作用于神经节苷脂以产生非唾液酸G.sub.M1。
查看更多

同类化合物

鞘磷酯 鞘氨醇半乳糖苷-3'-硫酸酯 西地芬戈 葡糖鞘氨醇半乳糖苷 脑苷脂类 脑苷脂D 脑苷脂 B 神经鞘氨醇半乳糖苷 神经酸酰胺 神经酰胺N-甲基氨基乙基膦酸酯 神经酰胺 神经节苷酯Gm3内酯 神经节苷酯GM1(牛脑) 神经节苷脂GM3 溶血神经酰胺三己糖苷 正二十四烷基二氢-葡糖脑苷脂 己酰神经鞘氨醇 大豆脑苷 I 双唾液酸神经节苷酯GD1A 双唾液酸神经节苷脂GD2 单唾液酸神经节苷酯 十四酰鞘氨醇 人脾脏葡糖苷酰鞘氨醇 二羟基神经酰胺 二十二烷酰胺,N-[1-[(b-D-吡喃葡萄糖氧基)甲基]-2,3-二羟基-5-十七碳烯基]-2-羟基-(9CI) 二十二烷酰胺,N-[(1S,2R,3E,7E,9E)-1-[(b-D-吡喃葡萄糖氧基)甲基]-2-羟基-8-甲基-3,7,9-十七碳三烯-1-基]-2-羟基-,(2R)- 二十二烷酰胺,N-[(1S,2R,3E)-2-羟基-1-(羟甲基)-3-十五碳烯基]- 乳酰基-N-脂酰基鞘氨醇(牛) 乳糖酰基鞘糖脂 乳糖酰基鞘氨醇 β-D-葡萄糖基C4-神经酰胺 alpha-半乳糖基-C16-神经酰胺 [(E,2S,3R)-3-羟基-2-[[(Z)-十八碳-9-烯酰基]氨基]十八碳-4-烯基]2-三甲基铵乙基磷酸酯盐 [(E,2S,3R)-3-羟基-2-[[(Z)-3-芘-1-基丙-2-烯酰基]氨基]十八碳-4-烯基]2-三甲基铵乙基磷酸酯盐 [(E,2S,3R)-3-羟基-2-[11-(芘-1-基磺酰基氨基)十一烷酰基氨基]十八碳-4-烯基]2-三甲基铵乙基磷酸酯盐 [(2R,3S,4S,5R,6R)-3,5-二羟基-2-(羟基甲基)-6-[(E,2S,3R)-3-羟基-2-(二十四烷酰基氨基)十八碳-4-烯氧基]四氢吡喃-4-基]氢硫酸盐 TNPAL-鞘磷脂 O-甘露糖基-(1-3)-O-甘露糖基-(1-4)-O-吡喃葡萄糖基-(1-1)-2-N-二十四烷酰基鞘氨醇 N-(NBD-氨基脲酰)沙丁胺醇 N-辛酰基神经酰胺-1-磷酸酯(铵盐) N-辛酰基4-羟基鞘氨醇(酿酒酵母) N-辛酰基-D-神经鞘氨醇 N-肉豆蔻酰-D-赤型-鞘氨醇 N-神经酰基-D-赤型鞘氨酰基磷酸胆碱 N-硬脂酰神经鞘氨醇 N-硬脂酰植物鞘氨醇 N-硬脂酰基-DL-二氢乳脑苷 N-硬脂酰-dl-二氢-葡糖脑苷脂 N-硬脂酰-D-鞘磷脂 N-癸酰-D-鞘胺醇